FDA-Referenced Cagrilintide Peptide | Adipotide/AOD9604 Substitute
Sequence Accuracy: 100% match to patent US20210137821A1, renal toxicity-free.
Dosing Innovation: C-terminal amidation extends t½ to 36h vs AOD9604's 12h.
Ideal For: Peptide replacement studies requiring patent clearance.
Quality Proof: MALDI-TOF sequencing ≥99.2% in COA.
Global Peptide Solutions Provider
Specializing in GMP-certified peptide R&D, production & distribution for biomedical research and healthcare sectors.
Core Competencies
• End-to-End Expertise: Molecular design to global cold chain logistics
• Scaled Capacity: 100,000+ units/month in 10,000㎡ ISO 13485 facility
• Quality Control: 3-stage testing (HPLC/MS dual verification, >99% purity)
• Global Reach: 50+ countries via US/EU/SG hubs with blockchain traceability
Flagship Products
▸ Weight Management: Semaglutide, Tirzepatide, Cagrilintide
▸ Tissue Repair: BPC-157 (multifunctional recovery)
▸ Next-Gen Solutions: Antimicrobial & anti-aging peptides
Operational Excellence
✓ Stability: 36-month validated shelf life at 25°C/60% RH
✓ Logistics: GPS-tracked cold chain with DDP clearance (72hr dispatch)
✓ Compliance: USP/EP standards & automated lyophilization
Client Support
• Shipping: 5-9 business days via DHL/FedEx/Dedicated Line
• Payment: Bank Transfer/Crypto/Alibaba Trade Assurance
• Guarantee: Damaged/lost order replacement & real-time tracking
Telegram: @HelenTT
Whatsapp:+12139973355
Контакти
Форма за контакт
FDA-Referenced Cagrilintide Peptide | Adipotide/AOD9604 Substitute 0 reviews
Write Your ReviewThere are no reviews yet.